Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
Public ClinicalTrials.gov record NCT05524571. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants With Active Thyroid Eye Disease (TED)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.
Study identification
- NCT ID
- NCT05524571
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 86 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 5, 2023 (Actual)
- Primary completion
- Feb 3, 2026 (Actual)
- Completion
- Mar 3, 2026 (Actual)
- Last update posted
- Apr 1, 2026
2023 – 2026
United States locations
- U.S. sites
- 15
- U.S. states
- 11
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site Number -1520 | Pasadena | California | 91107 | — |
| Site Number -1517 | San Francisco | California | 94143 | — |
| Site Number -1514 | Torrance | California | 90502 | — |
| Site Number -1510 | Sarasota | Florida | 34239 | — |
| Site Number -1516 | Louisville | Kentucky | 40202 | — |
| Site Number - 1526 | Livonia | Michigan | 48152 | — |
| Site Number - 1513 | Rochester | Minnesota | 55905 | — |
| Site Number - 1512 | Winston-Salem | North Carolina | 27157 | — |
| Site Number - 1525 | Portland | Oregon | 97239 | — |
| Site Number -1515 | Bellaire | Texas | 77401 | — |
| Site Number - 1524 | McAllen | Texas | 78503 | — |
| Site Number -1519 | San Antonio | Texas | 78215 | — |
| Site Number - 1521 | Seattle | Washington | 98104 | — |
| Site Number -1511 | Morgantown | West Virginia | 26506 | — |
| Site Number - 1518 | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 30 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05524571, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 1, 2026 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05524571 live on ClinicalTrials.gov.